# First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

> **NCT00456261** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 110 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00456261
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2010-02
- **Final completion:** 2012-09
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00456261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00456261, "First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00456261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*